The 4th Annual Kabuki Syndrome Foundation Research Conference to be held virtually on Friday, November 4, 2022. The Annual Conference...
      Join World BI and Redenlab for the 20th Clinical Trials Innovation Programme, to learn from experts in the drug development...
        MEDIA RELEASEFRIDAY 15 JULY 2022 As many as 70% of people who experience stuttering have a family member who also...

          Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia.

            Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for monitoring brain health.

              Redenlab is contributing to a study sponsored by the Australian Department of Defence and The University of Melbourne on speech biometrics and decision making in submariners

                Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.

                  Dr Geoff Stuart joins the Redenlab analytics team as Statistics Director. Geoff will be running the company’s clinical trials statistics program and data analytics development. He brings expertise in mathematical statistics and a background in experimental psychology.

                    Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers in understanding key issues in optimal ageing (including environmental, social and economic factors that underlie health and independence in ageing).

                      Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.

                        Professor Angela Morgan has been recognised for her outstanding leadership in advancing the diagnosis, prognosis and management of childhood speech disorders.

                          Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of Neurology and ERN EURO-NMD: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?

                            SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.

                              Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia

                                Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to tech development and science promotion, with a focus on his specialties of Parkinson’s disease and Multiple Sclerosis.

                                  Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.

                                    Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by USA and...

                                      Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

                                        Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.

                                          Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that is in-line with standards such as FDA 21 CFR Part 22.

                                            We are excited to announce that Redenlab Speech Scientists ranked top 1 AND 2 in the world for dysarthria (most common neuromuscular speech disorder)!

                                              Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.

                                                Describing the relationship between disease severity and speech metrics, through listener-based and objective acoustic analysis.

                                                  In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and sensitivity to change in vowel measurements.